Search filters

List of works by Leticia Toledo-Sherman

A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma

scientific article published on 24 January 2015

Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's Disease

scientific article published on 04 April 2019

Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems

scientific article published on 06 March 2019

Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).

scientific article published on 20 May 2013

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease

scientific article

Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.

scientific article

Emerging β-Sheet Rich Conformations in Supercompact Huntingtin Exon-1 Mutant Structures.

scientific article published on 13 June 2017

Erratum: Corrigendum: The promise and peril of chemical probes

scientific article published in November 2015

Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA.

scientific article published in October 2004

Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening

scientific article

Global kinase screening. Applications of frontal affinity chromatography coupled to mass spectrometry in drug discovery

scientific article published in March 2005

High-throughput virtual screening for drug discovery in parallel

scientific article

Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease

scientific article

Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.

scientific article

Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048 ⬇️

scientific article published on August 31, 2012

Molecular Mechanism of Stabilizing the Helical Structure of Huntingtin N17 in a Micellar Environment.

scientific article

Novel magnetic supports for small molecule affinity capture of proteins for use in proteomics

scientific article published in January 2004

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).

scientific article published on 8 August 2017

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models

scientific article published on 19 March 2019

Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction

scientific article published on 30 August 2020

Pharmaceutical Development for Huntington’s Disease ⬇️

scientific article published on September 2, 2011

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.

scientific article published on 6 May 2016

The promise and peril of chemical probes

scientific article

Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13

scientific article published on 31 October 2019

Paulina is supported by:

About Paulina

Help